Amplify Weight Loss Drug & Treatment ETF (THNR)

THNR Holdings Information

THNR is an equity ETF with a total of 22 individual holdings. The top holdings are Novo Nordisk stock at 13.48%, Eli Lilly and Company at 11.25%, Regeneron Pharmaceuticals at 6.67%, Amgen at 6.21%, and Chugai Pharmaceutical at 6.14%.

• Total Holdings: 22
• Top 10 Percentage: 69.81%
• Asset Class: Equity
• ETF Category: Health
• Assets: 4.08M
• PE Ratio: 18.43

Top 25 Holdings

As of Apr 23, 2026

Filter results

No.	Symbol	Name	% Weight	Shares
1	NVO	Novo Nordisk A/S	13.48%	13,608
2	LLY	Eli Lilly and Company	11.25%	529
3	REGN	Regeneron Pharmaceuticals, Inc.	6.67%	369
4	AMGN	Amgen Inc.	6.21%	749
5	TYO: 4519	Chugai Pharmaceutical Co., Ltd.	6.14%	4,600
6	ARWR	Arrowhead Pharmaceuticals, Inc.	5.85%	3,287
7	HKG: 1801	Innovent Biologics, Inc.	5.27%	20,000
8	SWX: ROP	Roche Holding AG	5.03%	510
9	HKG: 1093	CSPC Pharmaceutical Group Limited	4.97%	180,000
10	PFE	Pfizer Inc.	4.94%	7,606
11	LON: AZN	AstraZeneca PLC	4.85%	1,063
12	MRK	Merck & Co., Inc.	4.75%	1,763
13	TYO: 4507	Shionogi & Co., Ltd.	4.36%	9,300
14	ABBV	AbbVie Inc.	4.34%	907
15	SRRK	Scholar Rock Holding Corporation	2.24%	2,005
16	VKTX	Viking Therapeutics, Inc.	2.22%	2,818
17	GPCR	Structure Therapeutics Inc.	1.90%	1,738
18	CPH: ZEAL	Zealand Pharma A/S	1.83%	1,604
19	JNGHF	Jiangsu Hengrui Pharmaceuticals Co Ltd Ordinary Shares - Class H	1.31%	6,200
20	KRX: 128940	Hanmi Pharm. Co., Ltd.	1.27%	158
21	AGPXX	Short-Term Investment Trust - Invesco Government & Agency Portfolio	0.95%	39,342
22	n/a	OTHER ASSETS AND LIABILITIES	0.16%	151,364,154